<!DOCTYPE html>
Metformin for Li-Fraumeni Syndrome: A New Hope for Cancer Prevention?
Li-Fraumeni syndrome (LFS) is a rare inherited disorder that significantly increases the risk of developing various cancers. While risk-reducing mastectomy is an option, researchers are exploring new ways to prevent cancer in individuals with LFS, and metformin has emerged as a promising candidate.
Prior findings have inspired a shared protocol design for a randomized, non-placebo-controlled trial intended to assess whether the addition of metformin to cancer screening can impact cancer incidence among patients with LFS.
Understanding Li-Fraumeni Syndrome
LFS is caused by mutations in the TP53 gene, which plays a crucial role in suppressing tumor growth. Individuals with LFS have a high lifetime risk of developing cancers such as breast, brain, bone, and soft tissue sarcomas.
The Need for New Approaches to Prevention
While risk-reducing mastectomy can significantly lower the risk of breast cancer in LFS patients, it is not a cure-all and may not be suitable for everyone. Furthermore, the uncertainty surrounding cancer development can cause significant emotional distress for patients and their families.
Metformin: A Potential Game Changer
Metformin, a commonly used medication for type 2 diabetes, has shown potential as a chemopreventive agent for various cancers. It works by regulating cellular metabolism and inhibiting tumor growth.
Organizing a multidisciplinary strategy to evaluate the use of metformin in Li-Fraumeni syndrome (LFS) may show that primary prevention beyond risk-reducing mastectomy can have “an equally important voice” when it comes to treating patients, according to Payal Khincha, MBBS, MSHS.1
Khincha, a Lasker Clinical Research Scholar in the Division of Cancer Epidemiology and Genetics at the National Cancer Institute (NCI), spoke at the 7th International LFS Association Symposium about facilitating comprehensive, collaborative research efforts in LFS—a rare cancer predisposition hereditary disorder—and similar syndromes. In her presentation, Khincha specifically highlighted the ongoing work of an international network of researchers who aim to evaluate the ability of metformin to potentially prevent the development of cancer among at-risk individuals with LFS.
International Research Efforts
Several clinical trials are underway worldwide to assess the efficacy and safety of metformin in preventing cancer in LFS. These include:
* **MILI trial (UK):** A randomized, non-placebo-controlled trial in adults with LFS, comparing annual whole-body MRI alone with MRI plus metformin.
* **MILI-G trial (Germany):** A trial in children and adults with TP53 variants, starting in 2025.
* **MILI-Paed trial (Canada):** A trial evaluating metformin plus screening versus screening alone in children with LFS.
These trials will provide valuable data on the potential of metformin as a primary prevention strategy for LFS.
Future Directions
The research on metformin for LFS is still in its early stages, but the results so far are promising. If these trials demonstrate the effectiveness of metformin, it could revolutionize the way we approach cancer prevention in individuals with LFS.
“Let’s go deeper. Let’s dive deeper than what we can do as individuals,” Khincha said, emphasizing collaboration as a key component of the ongoing research in the LFS field. “This is going to be key to [seeing] what the outcome is.”
Learn More About LFS and Cancer Prevention:**
For more information about Li-Fraumeni syndrome, cancer prevention, and clinical trials, visit the websites of reputable organizations such as:
* The National Cancer Institute (NCI):
* The Li-Fraumeni Syndrome Association: